Palisade Bio (PALI) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.49% |
| Dec 31, 2025 | -15.22% |
| Sep 30, 2025 | -32.53% |
| Jun 30, 2025 | -21.96% |
| Mar 31, 2025 | -6.82% |
| Dec 31, 2024 | -3.05% |
| Sep 30, 2024 | -10.55% |
| Jun 30, 2024 | -16.31% |
| Mar 31, 2024 | -13.80% |
| Dec 31, 2023 | -10.62% |
| Sep 30, 2023 | -9.85% |
| Jun 30, 2023 | 2.72% |
| Mar 31, 2023 | -13.81% |
| Dec 31, 2022 | -7.66% |
| Sep 30, 2022 | 1.76% |
| Jun 30, 2022 | 0.73% |
| Mar 31, 2022 | 3.23% |
| Dec 31, 2021 | 5.62% |
| Sep 30, 2021 | 9.31% |
| Jun 30, 2021 | -16.67% |
| Mar 31, 2021 | 18.56% |
| Dec 31, 2020 | 16.87% |
| Sep 30, 2020 | 30.88% |
| Jun 30, 2020 | 32.50% |
| Mar 31, 2020 | 18.69% |
| Dec 31, 2019 | 10.05% |
| Sep 30, 2019 | 9.36% |
| Jun 30, 2019 | 7.38% |
| Mar 31, 2019 | 9.29% |
| Dec 31, 2018 | 7.71% |
| Sep 30, 2018 | 5.80% |
| Jun 30, 2018 | 5.56% |
| Mar 31, 2018 | 5.97% |
| Dec 31, 2017 | 1.92% |
| Sep 30, 2017 | -18.53% |
| Jun 30, 2017 | -6.69% |
| Mar 31, 2017 | -16.13% |
| Dec 31, 2016 | -18.01% |
| Sep 30, 2016 | -19.80% |
| Jun 30, 2016 | -10.06% |
| Mar 31, 2016 | -8.80% |
| Dec 31, 2015 | -7.24% |
| Sep 30, 2015 | -18.54% |